Xylo Technologies Ltd. (MDGS) Research

Xylo Technologies Ltd. operates as a technology-focused enterprise, providing a comprehensive range of medical devices and related products to international markets, encompassing the United States, Europe, Asia, and Israel. The company's diverse operations are organized into several distinct segments, including Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and other divisions. Among its medical innovations is the Medigus Ultrasonic Surgical Endostapler, an advanced endoscopy system specifically utilized for treating gastroesophageal reflux disease. Xylo Technologies also develops specialized biological gels, engineered to safeguard patients against biological threats and to minimize the intrusion of allergens and viruses through the upper respiratory passages and ocular areas. Beyond its healthcare offerings, the company maintains a significant presence in the digital sector. This includes furnishing a digital advertising platform, managing various online retail outlets for consumer products on the Amazon marketplace, and operating an online platform for event management and ticketing services. Furthermore, Xylo Technologies is actively engaged in pioneering wireless battery charging technologies for vehicles and developing modular electronic vehicles. The organization, which was previously known as Medigus Ltd., officially adopted its current name, Xylo Technologies Ltd., in April 2024. Established in 1999, the company maintains its corporate headquarters in Tel Aviv-Yafo, Israel.

Open Xylo Technologies Ltd. (MDGS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.